ProQR Therapeutics Analyst Ratings
ProQR Therapeutics Analyst Ratings
ProQR Therapeutics Analyst Ratings
Chardan Capital Upgrades ProQR Therapeutics to Buy, Announces $2 Price Target
ProQR Therapeutics Analyst Ratings
Buy Rating for ProQR Therapeutics: Robust RNA-Editing Patent Portfolio, Promising Preclinical Candidates, and Strong Financial Position
Citigroup Maintains Buy on ProQR Therapeutics, Lowers Price Target to $1.8
ProQR Therapeutics Analyst Ratings
ProQR Therapeutics Analyst Ratings
ProQR Therapeutics Analyst Ratings
Chardan Assigns New Price Target of $2 to ProQR Therapeutics, Keeps Neutral Rating
Cantor Fitzgerald Adjusts Price Target on ProQR Therapeutics to $4.50 From $5, Maintains Overweight Rating
Cantor Fitzgerald Maintains Overweight on ProQR Therapeutics, Lowers Price Target to $4.5
HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target
HC Wainwright Raises Price Target on ProQR Therapeutics to $5 From $1.50, Maintains Buy Rating
JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $5
Tesla To $175? Here Are 10 Other Price Target Changes For Friday
Raymond James Adjusts ProQR Therapeutics Price Target to $5 From $2, Maintains Outperform Rating
Cantor Fitzgerald Upgrades ProQR Therapeutics to Overweight From Neutral, Adjusts Price Target to $5 From $0.80
No Data